The risk of drug interactions increases when patients obtain products from unreputable sources
3:00 - Katie as the Bridge Between Academia and Industry Ben acknowledges Katie's unique ability to bridge the gap between academic standards and practical industry applications
Sihe Gene ASO Therapy SG12 Injection Approved for Clinical Use On March 9, 2026, Sihegen (Beijing) Biotechnology Co., Ltd
They often use their own patented medications, which may include a combination of substances like HCG, phentermine, and various vitamins
On April 15, 2026, FDA removed these seven peptides from 503A Category 2 by withdrawing their nominations
Oral small molecules beyond orforglipron, additional dual agonists, and standalone amylin agents are all in Phase 2, reflecting a field that is no longer betting on one approach